Clinical trials: PSA Progression
Prostate Cancer
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer.
- Trial name
- NCT00045123
- Testing
- tarenflurbil, adjuvant therapy
- Where
- 58 sites in United States
- Sponsor
- Myrexis Inc.
Prostate Cancer
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00054574
- Testing
- panitumumab
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer
RATIONALE: Calcitriol, a form of vitamin D, may be able to prevent or slow the growth of prostate cancer cells. PURPOSE: Phase II trial to study the effectiveness of calcitriol in treating patients who have a rising PSA level…
- Trial name
- NCT00004043
- Testing
- calcitriol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Adenocarcinoma, PSA Level Greater Than 0.2
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back.
- Conditions
- Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression
- Trial name
- NCT03501940
- Testing
- Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Andrei Iagaru
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Suspected Prostate Cancer (increased PSA Level)
Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)
Prostate cancer is the second most common type of cancer in men only after lung cancer, and accounts for ~3.8% of all deaths caused in men in 2018.
- Trial name
- ProstaCEST (NCT06669273)
- Testing
- CEST MRI sequence at 3T
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Clermont-Ferrand
Prostate Cancer
Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.
Prostate cancer biochemical recurrence (BCR) occurs in 20-50% of patients following radical prostatectomy or radiotherapy. Due to significant risk of side effects and uncertainty about the benefits, physicians and patients are…
- Trial name
- RCT-EPAII-BCR (NCT03753334)
- Testing
- MAG-EPA
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
PK and Dose Escalation and Expansion Study of DST-2970
This is a Phase I multi-center, open-label, study of DST-2970 to determine the MTD, overall safety/tolerability, PK/pharmacodynamic parameters, and efficacy in prostate cancer patients.The study will include a dose escalation…
- Trial name
- NCT04291664
- Testing
- Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- DisperSol Technologies, LLC
Prostate Cancer
Radium 223 Following Intermittent ADT
This is a multicentre, phase II, randomized, open label study to evaluate the efficacy and safety of monthly Radium 223 in prolonging the off treatment interval of men with localized prostate cancer receiving intermittent…
- Trial name
- RAND (NCT02656563)
- Testing
- Radium 223 Dichloride (Xofigo®)
- Where
- Canada
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
The purpose of this study is to measure the benefit of sorafenib in patients with a rising PSA after treatment with radiation therapy or surgery who are NOT receiving with androgen ablation therapy.
- Trial name
- NCT00694291
- Testing
- Sorafenib
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to…
- Trial name
- NCT00726596
- Testing
- hydroxychloroquine
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Rutgers, The State University of New Jersey
Cancer of Prostate, Cancer of the Prostate
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
This study will evaluate the feasibility, safety, and efficacy of intradermal vaccination of prostate cancer patients with alpha-type-1-polarized dendritic cells (DC1) loaded with apoptotic allogeneic tumor (LNCap).
- Conditions
- Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic
- Trial name
- NCT00970203
- Testing
- androgen ablation (AA), DC1 vaccine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Roswell Park Cancer Institute
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer).
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04033432
- Testing
- Recombinant EphB4-HSA Fusion Protein
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Recurrent Prostate Cancer, Stage I Prostate Cancer
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after…
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00103194
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Elevated Prostate Specific Antigen
Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)
The purpose of this study is to assess the impact of an empiric course of antibiotics for men with an elevated prostate-specific antigen (PSA) level.
- Trial name
- NCT00840294
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Prostate Cancer
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence…
- Trial name
- NCT04186845
- Testing
- rhPSMA-7.3 (18F) Injection, Positron emission tomography scan
- Where
- 28 sites in United States, Finland and 1 more
- Volunteers
- 391 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or…
- Trial name
- NCT03187990
- Testing
- [68Ga]PSMA-11, [18F]PSMA-1007
- Where
- Switzerland
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Irene Burger
PSA, Elevated PSA
Marker Driven Selection of Patients for Prostate Biopsy and Management
The purpose of this research study is to determine if the interpretation of multiparametric MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of blood and urine biomarkers is more effective…
- Conditions
- PSA, Elevated PSA, Prostate Cancer
- Trial name
- MDSelect (NCT04240327)
- Where
- United States
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- University of Miami
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT03456804
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
A Registry for Patients Treated on the Clinical Trial TAX 3503
The purpose of this study is to continue follow-up on patients who were treated on the study called TAX 3505 (MSK IRB #07-101). The sponsor of this study, has decided to end the study early, before all patients have completed all…
- Trial name
- NCT01813370
- Testing
- No intervention
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center